Based on this approach, a novel recombinant humanized PD‐L1/CTLA‐4 bispecific single‐domain antibody‐Fc fusion protein (KN046) was designed to bind to both PD‐L1 and CTLA‐4 and effectively enhance the killing of tumor cells. This evidence concerns the gene CTLA4 and neoplasm.